In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus

References

1. Almirante B., Pericás J. M., Miró J. M.. 2014; Role of ceftaroline fosamil in the treatment of bacteremia and infectious endocarditis. Enferm Infecc Microbiol Clin32:44–53 [CrossRef][PubMed]
   [Google Scholar]
2. Balke B., Hogardt M., Schmoldt S., Hoy L., Weissbrodt H., Häussler S.. 2006; Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis25:25–30 [CrossRef][PubMed]
   [Google Scholar]
3. Barber K. E., Werth B. J., Rybak M. J.. 2015; The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother70:505–509 [CrossRef][PubMed]
   [Google Scholar]
4. Baxi S. M., Chan D., Jain V.. 2015; Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature. Infection43:751–754 [CrossRef][PubMed]
   [Google Scholar]
5. Candel F. J., Baos E., Nieto M., Picazo J. J.. 2015; Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in intensive care medicine?. Rev Esp Quimioter28:214–216[PubMed]
   [Google Scholar]
6. Claeys K. C., Zasowski E. J., Casapao A. M., Lagnf A. M., Nagel J. L., Nguyen C. T., Hallesy J. A., Compton M. T., Kaye K. S. et al. 2016; Propensity matched analysis of early daptomycin versus vancomycin for methicillin-resistant S. aureus bloodstream infections: daptomycin improves outcomes regardless of vancomycin MIC. Antimicrob Agents Chemother in press doi: [CrossRef][PubMed]
   [Google Scholar]
7. Cunha B. A., Gran A.. 2015; Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy. Int J Antimicrob Agents46:225–226 [CrossRef][PubMed]
   [Google Scholar]
8. Duplesis C., Crum-Cianflone N. F.. 2011; Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther3:2466 [CrossRef][PubMed]
   [Google Scholar]
9. Frampton J. E.. 2013; Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia. Drugs73:1067–1094 [CrossRef][PubMed]
   [Google Scholar]
10. Holubar M., Meng L., Deresinski S.. 2016; Bacteremia due to methicillin-resistant Staphylococcus aureus: new therapeutic approaches. Infect Dis Clin N Am30:491–507[CrossRef]
    [Google Scholar]
11. Morosini M. I., Cercenado E., Ardanuy C., Torres C.. 2012; Phenotypic detection of resistance mechanisms in gram-positive bacteria. Enferm Infecc Microbiol Clin30:325–332 [CrossRef][PubMed]
    [Google Scholar]
12. Paladino J. A., Jacobs D. M., Shields R. K., Taylor J., Bader J., Adelman M. H., Wilton G. J., Crane J. K., Schentag J. J.. 2014; Use of ceftaroline after glycopeptide failure to eradicate methicillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations. Int J Antimicrob Agents44:557–563 [CrossRef][PubMed]
    [Google Scholar]
13. Poon H., Chang M. H., Fung H. B.. 2012; Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Ther34:743–765 [CrossRef][PubMed]
    [Google Scholar]
14. Sader H. S., Flamm R. K., Farrell D. J., Jones R. N.. 2012; Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE ceftaroline surveillance program. Clin Infect Dis55:S181–S186 [CrossRef][PubMed]
    [Google Scholar]
15. Sakoulas G., Moise P. A., Casapao A. M., Nonejuie P., Olson J., Okumura C. Y., Rybak M. J., Kullar R., Dhand A. et al. 2014; Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther36:1317–1333 [CrossRef][PubMed]
    [Google Scholar]
16. Saravolatz L., Pawlak J., Johnson L.. 2010; In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother54:3027–3030 [CrossRef][PubMed]
    [Google Scholar]
17. Sánchez García M., De la Torre M. A., Morales G., Peláez B., Tolón M. J., Domingo S., Candel F. J., Andrade R., Arribi A. et al. 2010; Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. J Am Med Ass303:2260–2264 [CrossRef][PubMed]
    [Google Scholar]
18. Tong S. Y., Nelson J., Paterson D. L., Fowler V. G., Howden B. P., Cheng A. C., Chatfield M., Lipman J., Van Hal S. et al. 2016; CAMERA2 study group and the Australasian Society for Infectious Diseases Clinical Research Network. Combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials17:170[CrossRef]
    [Google Scholar]
19. Tsuji B. T., Rybak M. J.. 2006; Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis54:73–77 [CrossRef][PubMed]
    [Google Scholar]
20. Yahav D., Shaked H., Goldberg E., Yassin S., Eliakim-Raz N., Paul M., Bishara J., Leibovici L.. 2016; Time trends in Staphylococcus aureus bacteremia, 1988–2010, in a tertiary center with high methicillin resistance rates. Infection in press doi: [CrossRef][PubMed]
    [Google Scholar]